Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × omipalisib × Tumor-Agnostic × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡